Zoledronic Acid Injection, Solution
Product Images NDC 25021-826

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Zoledronic Acid (NDC 25021-826). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sagent Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Zol09 0016 01

Chemical structure diagram of zoledronic acid showing its molecular components including imidazole and phosphonic acid groups.*

FDA Label Image

Zol09 0016 02

A bar chart titled 'Proportion of Complete Responders by Day 10 in Pooled HCM Studies' comparing zoledronic acid injection 4 mg (n=86) and pamidronate 90 mg (n=99). The y-axis shows the percentage of complete responders up to 100%. Zoledronic acid shows a higher response rate around 80% compared to pamidronate near 65%, with a reported p-value of 0.002 indicating statistical significance.*

FDA Label Image

Zol09 0020 03

Label for zoledronic acid injection 4 mg per 100 mL (0.04 mg/mL) intravenous infusion by Sagent Pharmaceuticals. The label includes storage instructions, composition details, and administration warnings. It indicates the product is sterile, preservative-free, and contains no natural rubber latex. Manufactured by Sagent Pharmaceuticals, Schaumburg, IL, made in Switzerland.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.